VOR BIOPHARMA INC. - COMMON STOCK

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

05 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

11 May 2023 16:05:02 By Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

18 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

23 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

21 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

16 Feb 2023 12:00:00 By Nasdaq GlobeNewswire

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

19 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference

12 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

07 Dec 2022 07:45:00 By Nasdaq GlobeNewswire

First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

07 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

22 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

10 Nov 2022 16:15:00 By Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

01 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer

12 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

11 Oct 2022 08:00:02 By Nasdaq GlobeNewswire

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

28 Sep 2022 08:00:00 By Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

06 Sep 2022 16:15:00 By Nasdaq GlobeNewswire

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

11 Aug 2022 16:15:00 By Nasdaq GlobeNewswire

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

10 Jun 2022 08:00:00 By Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

01 Jun 2022 08:00:01 By Nasdaq GlobeNewswire